Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Cash: 2009-2024

Historic Change in Cash for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to -$18.2 million.

  • Cytokinetics' Change in Cash rose 206.12% to $152.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $181.3 million, marking a year-over-year increase of 443.38%. This contributed to the annual value of -$18.2 million for FY2024, which is 139.31% down from last year.
  • Per Cytokinetics' latest filing, its Change in Cash stood at -$18.2 million for FY2024, which was down 139.31% from $46.2 million recorded in FY2023.
  • Cytokinetics' Change in Cash's 5-year high stood at $46.6 million during FY2020, with a 5-year trough of -$45.5 million in FY2022.
  • Its 3-year average for Change in Cash is -$5.8 million, with a median of -$18.2 million in 2024.
  • As far as peak fluctuations go, Cytokinetics' Change in Cash soared by 899.45% in 2020, and later crashed by 253.24% in 2022.
  • Over the past 5 years, Cytokinetics' Change in Cash (Yearly) stood at $46.6 million in 2020, then tumbled by 36.24% to $29.7 million in 2021, then crashed by 253.24% to -$45.5 million in 2022, then spiked by 201.61% to $46.2 million in 2023, then tumbled by 139.31% to -$18.2 million in 2024.